Oligonucleotide Array Analysis of the HER2 Amplicon in Breast Cancers

被引：0
|
作者：
Lytvak, I. [1 ]
Gunn, S. R. [1 ]
Yeh, I. [1 ]
机构：
[1] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA
来源：
MODERN PATHOLOGY | 2010年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
263
引用
收藏
页码：61A / 61A
页数：1
相关论文
共 50 条
  • [41] Comparative Pathologic Analysis of Breast Cancers Classified as HER2/neu-Amplified by FISH using a Standard HER2/CEP17 Dual Probe and an Alternative HER2/LIS1 Dual Probe: An Analysis of 1201 Cancers
    Zare, Somaye
    Lin, Leo
    Alghamdi, Abrar G.
    Roma, Andres
    Hasteh, Farnaz
    Dell'Aquila, Marie
    Fadare, Oluwole
    LABORATORY INVESTIGATION, 2018, 98 : 117 - 117
  • [42] HER2-low Breast Cancers: Comparison of HER2 Scores by Immunohistochemistry and Oncotype DX
    Chen, Hui
    Wu, Yun
    Ding, Qingqing
    Huo, Lei
    Khazai, Laila
    Sahin, Aysegul
    Albarracin, Constance
    LABORATORY INVESTIGATION, 2023, 103 (03) : S114 - S114
  • [43] HER2 somatic mutations are associated with poor survival in HER2-negative breast cancers
    Wang, Tonghui
    Xu, Ye
    Sheng, Shuyan
    Yuan, Hua
    Ouyang, Tao
    Li, Jinfeng
    Wang, Tianfeng
    Fan, Zhaoqing
    Fan, Tie
    Lin, Benyao
    Xie, Yuntao
    CANCER SCIENCE, 2017, 108 (04): : 671 - 677
  • [44] Characteristics of HER2 FISH-Equivocal Breast Cancers and the Impacts on HER2 Status of 2018 ASCO/CAP Guideline
    Kong, Hui
    Bai, Qianming
    Lu, Hongfen
    Zhou, Xiaoyan
    Yang, Wentao
    LABORATORY INVESTIGATION, 2019, 99
  • [45] HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline
    Yao-Shan Fan
    Carmen E. Casas
    Jinghong Peng
    Melanie Watkins
    Lynn Fan
    Jennifer Chapman
    Offiong Francis Ikpatt
    Carmen Gomez
    Wei Zhao
    Isildinha M. Reis
    Breast Cancer Research and Treatment, 2016, 155 : 457 - 462
  • [46] HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline
    Fan, Yao-Shan
    Casas, Carmen E.
    Peng, Jinghong
    Watkins, Melanie
    Fan, Lynn
    Chapman, Jennifer
    Ikpatt, Offiong Francis
    Gomez, Carmen
    Zhao, Wei
    Reis, Isildinha M.
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 155 (03) : 457 - 462
  • [47] Different Mechanisms for Acquired Resistance to Trastuzumab and Lapatinib in HER2 Positive Breast Cancers: Role of ER and HER2 Reactivation
    Wang, Y-C
    Hennessy, B.
    Ward, McAnnich R.
    Rimawi, M.
    Huang, C.
    Mills, G. B.
    Osborne, C. K.
    Schiff, R.
    CANCER RESEARCH, 2009, 69 (24) : 526S - 526S
  • [48] Characteristics of HER2 FISH-Equivocal Breast Cancers and the Impacts on HER2 Status of 2018 ASCO/CAP Guideline
    Kong, Hui
    Bai, Qianming
    Lu, Hongfen
    Zhou, Xiaoyan
    Yang, Wentao
    MODERN PATHOLOGY, 2019, 32
  • [49] The use of long-read sequencing to determine the structure of the Her2 amplicon in breast cancer
    Rosenfeld, Jeffrey
    Goodwin, Sara
    Ganesan, Shridar
    CANCER RESEARCH, 2017, 77
  • [50] Breast Cancer Biomarker Changes and Correlations with HER2 Change in ER Positive, HER2 Negative Breast Cancers Treated with Neoadjuvant Endocrine Therapy
    Huang, Wei
    Tyburski, Haley
    Finkelman, Brian
    Turner, Bradley
    Weiss, Anna
    Dhakal, Ajay
    Skinner, Kristin
    Hicks, David
    Zhang, Huina
    LABORATORY INVESTIGATION, 2024, 104 (03) : S175 - S176
12345